This was a federal case. The applicant was Galderma Canada Inc., while the respondent was the Attorney General of Canada. This judicial review application under ss. 18, 18.1, and 18.2 of the Federal Courts Act challenged the decision of the Patented Medicine Prices Review Board asserting jurisdiction over the medicine Differin 0.1 and ordering Galderma to file prescribed pricing information with the Board for the medicine for the period between Jan. 1, 2010 and Mar. 14, 2016. The hearing was set on Nov. 22, 2023. No financial award was specified.